Long-term Effect of Hematopoietic Stem Cell Transplantation on the
Quality of Life of Patients with β-thalassemia Major in Guangxi, China - A
Cross-sectional Study

Lu      Zhai; Yuhua      Liu; Rongrui      Huo; Zhaofang      Pan; Yaqun      Zhang; Zhi      Li; Fang      Li; Jing      Fan; Wei      Wei

doi:10.2174/1574888X17666220509223421

Abstract

Objective: The purpose of our study was to compare the quality of life (QOL) of patients with hematopoietic stem cell transplantation (HSCT) for more than 2 years for β -thalassemia major (β-TM) with that of β-TM patients with conventional therapy (blood infusion and iron chelation) and that of the general population.

Methods: This was a cross-sectional comparative study on the QOL of 225 β-TM patients treated with blood transfusion and iron chelation therapy, 133 β-TM patients who had undergone HSCT or 270 ageand sex-matched healthy individuals from Guangxi, China. Child-self and parent-proxy reports of the PedsQL 4.0 Generic Core Scales were used to prospectively evaluate QOL.

Results: The incidence of acute GVHD was 14.3% (grade III-IV in 4.5% of patients), and that of chronic GVHD was 3.8%. This was lower than that of previous studies since the inclusion of anti-thymocyte globulin (ATG). Patients who underwent transplantation from a voluntary donor had higher QOL scores and lower rates of acute GVHD, chronic GVHD and comorbidities than those receiving stem cell sources from an HLA mismatched related donor (haploidentical donor). Transplants with PBSCs or UCBT, PBSCT+BMT, BMT, or BMT+UCBT as stem cell sources did not have any impact on QOL. The QOL of β-TM patients was very similar to that of the general population. More complications (P<0.001), shorter post-transplantation time (P<0.001), and older age at HSCT (P=0.01) were associated with poorer child QOL (P=0.020). Additional analyses investigating QOL of β-TM patients receiving conventional treatment with β-TM revealed poorer outcomes than the cohort of transplanted patients.

Conclusion: β-TM patients can be cured by HSCT and regain QOL as good as that of the general population. β-TM patients are suggested to undergo HSCT as soon as possible to avoid complications related to iron overload and blood infusion.

Keywords: Haploidentical hematopoietic stem cell transplantation, unrelated hematopoietic stem cell transplantation, blood infusion, iron chelation, β-thalassemia major, quality of life.

« Previous Next »

Graphical Abstract

[1]
Caocci G, Pisu S, Argiolu F, et al. Decision-making in adult thalassemia patients undergoing unrelated bone marrow transplantation: Quality of life, communication and ethical issues. Bone Marrow Transplant  2006; 37(2): 165-9.
 [http://dx.doi.org/10.1038/sj.bmt.1705236] [PMID:  16299541]

[2]
Caocci G, Efficace F, Ciotti F, et al. Prospective assessment of health-related quality of life in pediatric patients with beta-thalassemia following hematopoietic stem cell transplantation. Biology of blood and marrow transplantation. J American Society for Blood and Marrow Transplantation  2011; 17(6): 861-6.

[3]
La Nasa G, Caocci G, Efficace F, et al. Long-term health-related quality of life evaluated more than 20 years after hematopoietic stem cell transplantation for thalassemia. Blood  2013; 122(13): 2262-70.
 [http://dx.doi.org/10.1182/blood-2013-05-502658] [PMID:  23958950]

[4]
Cheuk DK, Mok AS, Lee AC, et al. Quality of life in patients with transfusion-dependent thalassemia after hematopoietic SCT. Bone Marrow Transplant  2008; 42(5): 319-27.
 [http://dx.doi.org/10.1038/bmt.2008.165] [PMID:  18560410]

[5]
Patel S, Swaminathan VV, Mythili VS, et al. Quality Matters - hematopoietic stem cell transplantation versus transfusion and chelation in thalassemia major. Indian Pediatr  2018; 55(12): 1056-8.
 [http://dx.doi.org/10.1007/s13312-018-1441-y] [PMID:  30745477]

[6]
Uygun V, Tayfun F, Akcan M, et al. Quality of life assessment in hematopoietic stem cell transplantation performed on thalassemia major patients. Pediatr Hematol Oncol  2012; 29(5): 461-71.
 [http://dx.doi.org/10.3109/08880018.2012.693577] [PMID:  22712884]

[7]
Raj R, Ramachandran S Jr, Uppuluri R Jr, et al. A Single centre study from India on the impact on quality of life in thalassaemia major – hsct versus long term transfusion. Biol Blood Marrow Transplant  2016; 22(3): S192.
 [http://dx.doi.org/10.1016/j.bbmt.2015.11.576]

[8]
Javanbakht M, Keshtkaran A, Shabaninejad H, Karami H, Zakerinia M, Delavari S. Comparison of blood transfusion plus chelation therapy and bone marrow transplantation in patients with β-thalassemia: Application of SF-36, EQ-5D, and visual analogue scale measures. Int J Health Policy Manag  2015; 4(11): 733-40.
 [http://dx.doi.org/10.15171/ijhpm.2015.113] [PMID:  26673333]

[9]
Khalid S, Hamid S, Goldman R, et al. Impact of bone marrow transplant vs. supportive care on health related quality of life in patients with severe thalassemia in a lower middle-income country. Biol Blood Marrow Transplant  2019; 25(3): S69.
 [http://dx.doi.org/10.1016/j.bbmt.2018.12.154]

[10]
Caocci G, Vacca A, Piras E, et al. Return to normal life after hematopoietic stem cell transplantation for thalassemia: A study of patients transplanted from matched sibling donors. Bone Marrow Transplant  2016; 51(12): 1640-1.
 [http://dx.doi.org/10.1038/bmt.2016.243] [PMID:  27643871]

[11]
Badawy SM, Beg U, Liem RI, Chaudhury S, Thompson AA. A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy. Blood Adv  2021; 5(2): 570-83.
 [http://dx.doi.org/10.1182/bloodadvances.2020002948] [PMID:  33496753]

[12]
Chao R. Investigation and evaluation of quality of life after hematopoietic stem cell transplantation in children with β-thalassemia major. Guangxi Medical University 2013.

[13]
He J, Zeng H, Zhu L, Li H, Shi L, Hu L. Prevalence and spectrum of thalassaemia in Changsha, Hunan province, China: Discussion of an innovative screening strategy. J Genet  2017; 96(2): 327-32.
 [http://dx.doi.org/10.1007/s12041-017-0779-6] [PMID:  28674233]

[14]
Lucarelli G, Galimberti M, Giardini C, et al. Bone marrow transplantation in thalassemia  Annals of the New York Academy of	Sciences 1998; 850: 270: 27  1998.

[15]
Flowers MED, Inamoto Y, Carpenter PA. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood  2011; 117(11): 3214-9.

[16]
Betts M, Flight PA, Paramore LC, Tian L. Milenković D, Sheth S. Systematic literature review of the burden of disease and treatment for transfusion-dependent β-thalassemia. Clin Ther  2020; 42(2): 322-337.e2.
 [http://dx.doi.org/10.1016/j.clinthera.2019.12.003] [PMID:  31882227]

[17]
Safizadeh H, Farahmandinia Z, Nejad SS, Pourdamghan N, Araste M. Quality of life in patients with thalassemia major and intermedia in kerman-iran (I.R.). Mediterr J Hematol Infect Dis  2012; 4(1): e2012058.
 [http://dx.doi.org/10.4084/mjhid.2012.058] [PMID:  23170187]

[18]
Sinlapamongkolkul P, Surapolchai P. Health-related quality of life in thai children with thalassemia as evaluated by PedsQL and EQ-5D-Y: A single-center experience. Mediterr J Hematol Infect Dis  2020; 12(1): e2020036.
 [http://dx.doi.org/10.4084/mjhid.2020.036] [PMID:  32670514]

[19]
Töret E. , Karadaş NÖ, Gökçe NÖ, et al  Quality of life and depression in turkish patients with β-thalassemia major: A cross-sectional study. Hemoglobin  2018; 42(5-6): 326-9.
 [http://dx.doi.org/10.1080/03630269.2018.1551231] [PMID:  30672351]

[20]
Yasmeen H, Hasnain S. Quality of life of pakistani children with β-thalassemia major. Hemoglobin  2018; 42(5-6): 320-5.
 [http://dx.doi.org/10.1080/03630269.2018.1553183] [PMID:  30700180]

[21]
Floris F, Comitini F, Leoni G, et al. Quality of life in Sardinian patients with transfusion-dependent Thalassemia: A cross-sectional study. Qual Life Res  2018; 27(10): 2533-9.
 [http://dx.doi.org/10.1007/s11136-018-1911-7] [PMID:  29922915]

[22]
Shah FT, Sayani F, Trompeter S, et al. Challenges of blood transfusions in β-thalassemia. Blood Rev  2019; 37: 100588.

[23]
Choudhry VP. Quality of life in thalassemia major. Indian J Pediatr  2018; 85(11): 957-8.
 [http://dx.doi.org/10.1007/s12098-018-2792] [PMID:  30242607]

Rights & Permissions Print Cite

Article Metrics

4

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1574888X17666220509223421	Print ISSN 1574-888X
Publisher Name Bentham Science Publisher	Online ISSN 2212-3946

Current Stem Cell Research & Therapy

Long-term Effect of Hematopoietic Stem Cell Transplantation on the Quality of Life of Patients with β-thalassemia Major in Guangxi, China - A Cross-sectional Study

Abstract Play Pause

Graphical Abstract

Related Books

Abstract